May 24 Novo Nordisk A/S

* Says recommendation for approval was based on data from clinical trials of IDegLira

* 16-0 vote in favor of approval from FDA advisory committee Source text for Eikon: Further company coverage: (Bengaluru Newsroom +91 80 6749-1130; within U.S. +1 646 223 8780)



http://feeds.reuters.com/~r/reuters/...0/idUSASC08R5I